NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

McDonagh M, Peterson K, Carson S, et al. Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet]. Portland (OR): Oregon Health & Science University; 2010 Jul.

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Drug Class Review: Atypical Antipsychotic Drugs

Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet].

Show details

References

1.
Liberati A, Altman D, Telzlaff J, Mulrow C, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–W94. [PubMed: 19622512]
2.
Diagnostic and statistical manual of mental disorders : DSM-IV. 4th ed . Washington, DC: American Psychiatric Association; 1994.
3.
Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C. Important issues in the drug treatment of schizophrenia. Schizophr Bull. 1980;6(1):70–87. [PubMed: 6102795]
4.
Mirakhur A, Craig D, Hart DJ, McIlroy SP, Passmore AP. Behavioural and psychological syndromes in Alzheimer’s disease. Int J Geriatr Psychiatry. 2004 November;19(11):1035–1039. [PubMed: 15481075]
5.
Center for Disease Control and Prevention. Prevalence of Autism Spectrum Disorders -- Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR surveillance summaries. 2009;58(SS10):1–20. [PubMed: 20023608]
6.
Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol. 2006;59(10):1040–1048. [PubMed: 16980143]
7.
Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. Publication No. 06-0046. 2006. Criteria for distinguishing effectiveness from efficacy trials in systematic reviews. [PubMed: 20734508]
8.
Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3 Suppl):21–35. [PubMed: 11306229]
9.
Centers for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. 2nd edition. York, UK: NHS Centre for Reviews and Dissemination; 2001. p. 4.
10.
Owens DK, Lohr KN, Atkins Dea. Agency for Healthcare Research and Quality. Methods Guide for Comparative Effectiveness Reviews [posted July 2009]. 2009. Grading the strength of a body of evidence when comparing medical interventions. [PubMed: 19595577]
11.
Owens DK, Lohr KN, Atkins D, et al. Grading the strength of a body of evidence when comparing medical interventions: Agency for Healthcare Research and Quality and the Effective Health Care Program. J Clin Epidemiol. 2009. In Press. [PubMed: 19595577]
12.
American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56. [PubMed: 15000267]
13.
Lehman AF, Steinwachs DM. Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull. 1998;24(1):11–20. [PubMed: 9502543]
14.
Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004;30(2):193–217. [PubMed: 15279040]
15.
Lehman AF, Steinwachs DM. Evidence-based psychosocial treatment practices in schizophrenia: lessons from the patient outcomes research team (PORT) project. Journal of the American Academy of Psychoanalysis & Dynamic Psychiatry. 2003;31(1):141–154. [PubMed: 12722892]
16.
Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 1998;24(1):1–10. [PubMed: 9502542]
17.
Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331(7521):897–900. [PMC free article: PMC1255806] [PubMed: 16223826]
18.
Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105–3124. [PubMed: 15449338]
19.
Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534–2544. [PubMed: 12759325]
20.
Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691. [PubMed: 9250266]
21.
Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry. 2004 Dec;65(12):1624–1633. [PubMed: 15641867]
22.
Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. Am J Addict. 2007 Jul–Aug;16(4):260–268. [PubMed: 17661193]
23.
Alvarez E, Ciudad A, Olivares JM, Bousono M, Gomez JC. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. J Clin Psychopharmacol. 2006 Jun;26(3):238–249. [PubMed: 16702888]
24.
Apiquian R, Fresan A, Herrera K, et al. Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine. International Journal of Neuropsychopharmacology. 2003 Dec;6(4):403–408. [PubMed: 14604455]
25.
Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64(5):598–604. [PubMed: 12755665]
26.
Azorin JM, Spiegel R, Remington G, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry. 2001;158(8):1305–1313. [PubMed: 11481167]
27.
Bellack AS, Schooler NR, Marder SR, Kane JM, Brown CH, Yang Y. Do Clozapine and Risperidone Affect Social Competence and Problem Solving? Am J Psychiatry. 2004 Feb;161(2):364–367. [PubMed: 14754789]
28.
Bitter I, Dossenbach MR, Brook S, et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):173–180. [PubMed: 14687871]
29.
Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry. 1998;155(4):499–504. [PubMed: 9545995]
30.
Breier A, et al. Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia. Am J Psychiatry. 2005 Oct;162:1879–1887. [PubMed: 16199834]
31.
Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry. 1999;45(4):403–411. [PubMed: 10071708]
32.
Bristol-Myers S. CN-138-003. 2005. A multicenter, double-blind randomized, comparative study on aripiprazole and olanzapine in the treatment of patients with acute schizophrenia.
33.
Canive JM, Miller GA, Irwin JG, et al. Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design. Psychopharmacol Bull. 2006;39(1):105–116. [PubMed: 17065975]
34.
Chan H-Y, Lin W-W, Lin S-K, et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry. 2007 Jan;68(1):29–36. [PubMed: 17284127]
35.
Chiu C-C, Chen K-P, Liu H-C, Lu M-L. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. J Clin Psychopharmacol. 2006 Oct;26(5):504–507. [PubMed: 16974193]
36.
Chowdhury AN, Mukherjee A, Ghosh K, Chowdhury S, Das Sen K. Horizon of a new hope: Recovery of schizophrenia in India. International Medical Journal. 1999;6(3):181–185.
37.
Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005 Jan;15(1):111–117. [PubMed: 15572280]
38.
Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 2006 Dec;189(2):259–266. [PubMed: 17058105]
39.
Conley R, et al. Risperidone, quetiapine, and fluphenazine in the treatment of patiens with therapy-refractory schizophrenia. Clin Neuropharmacol. 2005 Jul–Aug;28:163–168. [PubMed: 16062094]
40.
Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: A double-blind, crossover study. J Clin Psychopharmacol. 2003 Dec;23(6):668–671. [PubMed: 14624201]
41.
Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158(5):765–774. [PubMed: 11329400]
42.
Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla M, Martinez-Garcia O, Llorca J, Luis Vazquez-Barquero J. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry. 2006 11/21/2007;67(10):1511–1521. [PubMed: 17107241]
43.
Daniel DG, Goldberg TE, Weinberger DR, et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: A pilot study. Am J Psychiatry. 1996;153(3):417–419. [PubMed: 8610833]
44.
Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007 Jul;93(1–3):117–130. [PubMed: 17466492]
45.
Dollfus S, Olivier V, Chabot B, Deal C, Perrin E. Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. Schizophr Res. 2005 Oct 15;78(2–3):157–159. [PubMed: 16102942]
46.
Garyfallos G, Dimelis D, Kouniakis P, et al. Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels. European Psychiatry: the Journal of the Association of European Psychiatrists. 2003;18(6):320–321. [PubMed: 14611929]
47.
Gureje O, Miles W, Keks N, et al. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res. 2003;61(2–3):303–314. [PubMed: 12729882]
48.
Huang T-L, Chen J-F. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res. 2005 Dec 1;80(1):55–59. [PubMed: 15964176]
49.
Jerrell JM. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr Bull. 2002;28(4):589–605. [PubMed: 12795493]
50.
Jeste DV, Barak Y, Madhusoodanan S, Grossman F, Gharabawi G. International Multisite Double-Blind Trial of the Atypical Antipsychotics Risperidone and Olanzapine in 175 Elderly Patients with Chronic Schizophrenia. Am J Geriatr Psychiatry. 2003;11(6):638–647. [PubMed: 14609804]
51.
Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007 Feb;90(1–3):147–161. [PubMed: 17092691]
52.
Keefe R, et al. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res. 2006;81:1–15. [PubMed: 16202565]
53.
Keks NA, Ingham M, Khan A, Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatry. 2007;191:131–139. [PubMed: 17666497]
54.
Kern RS, Green MF, Cornblatt BA, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 2006 Aug;187(3):312–320. [PubMed: 16810506]
55.
Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Ascher-Svanum H, Siris SG. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol. 2006a Apr;26(2):157–162. [PubMed: 16633144]
56.
Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol. 1995;15(1 Suppl 1):45S–51S. [PubMed: 7537287]
57.
Knegtering H, Boks M, Blijd C, Castelein S, van den Bosch RJ, Wiersma D. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther. 2006 Jul–Sep;32(4):315–326. [PubMed: 16709552]
58.
Knegtering R, Castelein S, Bous H, et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol. 2004;24(1):56–61. [PubMed: 14709948]
59.
Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2006 Jun;63(6):622–629. [PubMed: 16754835]
60.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223. [PubMed: 16172203]
61.
Lindenmayer JP, Iskander A, Park M, et al. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry. 1998;59(10):521–527. [PubMed: 9818633]
62.
McCue RE, Waheed R, Urcuyo L, et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry. 2006 Nov;189:433–440. [PubMed: 17077434]
63.
McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007 Jul;164(7):1050–1060. [PubMed: 17606657]
64.
McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006 Apr;163(4):600–610. [PubMed: 16585434]
65.
McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004;65( Suppl 18):47–56. [PubMed: 15600384]
66.
Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) Arch Gen Psychiatry. 2003;60(1):82–91. [PubMed: 12511175]
67.
Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther. 2001;23(11):1839–1854. [PubMed: 11768836]
68.
Naber D, Riedel M, Klimke A, et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand. 2005 Feb;111(2):106–115. [PubMed: 15667429]
69.
Potkin SG, Gharabawi GM, Greenspan AJ, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res. 2006 Jul;85(1–3):254–265. [PubMed: 16797162]
70.
Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic iith a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003b;60(7):681–690. [PubMed: 12860772]
71.
Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry. 2000;57(3):249–258. [PubMed: 10711911]
72.
Riedel M, et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2005 Nov;255:432–437. [PubMed: 16267634]
73.
Ritchie C, et al. A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. Int J Geriatr Psychiatry. 2006;21(2):171–179. [PubMed: 16416458]
74.
Robinson DG, Woerner MG, Napolitano B, et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry. 2006 Dec;163(12):2096–2102. [PubMed: 17151160]
75.
Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, Controlled, Double-Blind Multicenter Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients With Schizophrenia or Schizoaffective Disorder. Am J Psychiatry. 2004 Oct;161(10):1837–1847. [PubMed: 15465981]
76.
Sirota P, Pannet I, Koren A, Tchernichovsky E. Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Human Psychopharmacology. 2006 Jun;21(4):227–234. [PubMed: 16783811]
77.
Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry. 2007 Mar;164(3):415–427. [PubMed: 17329466]
78.
Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006 Apr;163(4):611–622. [PubMed: 16585435]
79.
Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001;49(1):52–63. [PubMed: 11163780]
80.
Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997;17(5):407–418. [PubMed: 9315992]
81.
van Bruggen J, Tijssen J, Dingemans P, Gersons B, Linszen D. Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. Int Clin Psychopharmacol. 2003;18(6):341–346. [PubMed: 14571154]
82.
Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159(2):255–262. [PubMed: 11823268]
83.
Voruganti L, Awad A, Parker G, et al. Cognition, functioning and quality of life in schizophrenia treatment: Results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research. 2007 2007 Nov;96:1–3. 146–155. [PubMed: 17728106]
84.
Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimon R. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2000a;24(6):911–922. [PubMed: 11041534]
85.
Wang X, Savage R, Borisov A, et al. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. J Psychiatr Res. 2006 Oct;40(7):669–676. [PubMed: 16762371]
86.
Wu R-R, Zhao J-P, Liu Z-N, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006 Jul;186(4):572–578. [PubMed: 16601995]
87.
Yamashita H, Mori K, Nagao M, Okamoto Y, Morinobu S, Yamawaki S. Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population. J Clin Psychiatry. 2004 Nov;65(11):1525–1530. [PubMed: 15554767]
88.
Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry. 2006 Jul;67(7):1093–1103. [PubMed: 16889453]
89.
Arango C, Robles O, Parellada M, et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry. 2009;18(7):418–428. [PubMed: 19198920]
90.
AstraZeneca. (D1444C00133). 2006. A 6-week, Multicenter, Double-blind, Double-dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL™) and Placebo in the Treatment of Acutely Ill Patients with Schizophrenia.
91.
Boter H, Peuskens J, Libiger J, et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST) Schizophr Res. 2009 Dec;115(2–3):97–103. [PubMed: 19819114]
92.
Byerly MJ, Nakonezny PA, Rush AJ. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial. Psychiatry Res. 2008 May 30;159(1–2):115–120. [PubMed: 18295343]
93.
Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry. 2009 Jun;166(6):691–701. [PubMed: 19411369]
94.
Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S20–28. [PubMed: 18334909]
95.
Deberdt W, Lipkovich I, Heinloth AN, et al. Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder. Therapeutics and Clinical Risk Management. 2008;4(4):713–720. [PMC free article: PMC2621385] [PubMed: 19209252]
96.
Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009 Mar 15;65(6):510–517. [PubMed: 18986646]
97.
Hatta K, Sato K, Hamakawa H, et al. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophr Res. 2009;113(1):49–55. [PubMed: 19553086]
98.
Ingole S, Belorkar NR, Waradkar P, Shrivastava M. Comparison of effects of olanzapine and risperidone on body mass index and blood sugar level in schizophrenic patients. Indian J Physiol Pharmacol. 2009 Jan–Mar;53(1):47–54. [PubMed: 19810576]
99.
Kane JM, Osuntokun O, Kryzhanovskaya LA, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry. 2009 Apr;70(4):572–581. [PubMed: 19323965]
100.
Karagianis J, Grossman L, Landry J, et al. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS Study. Schizophr Res. 2009;113(1):41–48. [PubMed: 19535229]
101.
Kelly DL, Conley RR, Love RC, Morrison JA, McMahon RP. Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine. Ann Clin Psychiatry. 2008 Apr–Jun;20(2):71–78. [PubMed: 18568578]
102.
Kluge M, Schuld A, Himmerich H, et al. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol. 2007 Dec;27(6):662–666. [PubMed: 18004133]
103.
Lindenmayer JP. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study. Psychopharmacol Bull. 2008;41(3):11–35. [PubMed: 18779774]
104.
Meltzer HY, Bobo WV, Roy A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2008 Feb;69(2):274–285. [PubMed: 18232726]
105.
Moller H-J, Johnson S, Mateva T, et al. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. Int Clin Psychopharmacol. 2008 Mar;23(2):95–105. [PubMed: 18301124]
106.
Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008 Jul;69(7):1046–1056. [PubMed: 18605811]
107.
Newcomer JW, Ratner RE, Eriksson JW, et al. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry. 2009 Apr;70(4):487–499. [PMC free article: PMC3703648] [PubMed: 19358783]
108.
Patel JK, Buckley PF, Woolson S, et al. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFÉ study. Schizophr Res. 2009;111(1–3):9–16. [PubMed: 19398192]
109.
Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry. 2007 Nov;68(11):1733–1740. [PubMed: 18052567]
110.
Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007 Oct;68(10):1492–1500. [PubMed: 17960962]
111.
Sacchetti E, Galluzzo A, Valsecchi P, et al. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res. 2009 Aug;113(1):112–121. [PubMed: 19606529]
112.
Sacchetti E, Valsecchi P, Parrinello G, Group Q. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial. Schizophr Res. 2008 Jan;98(1–3):55–65. [PubMed: 17933497]
113.
Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. Schizophr Res. 2008 Apr;101(1–3):266–272. [PubMed: 18262771]
114.
Plough Schering. 2004. (Study A7501001) A double-blind, parallel, multicenter study to assess the effect of asenapine, quetiapine (ESroquel), and placebo on the QTc interval in patients with schizophrenia.
115.
Plough Schering. 2006. (Study 25543) A multicenter, double-blind, flexible-dose, 6-month trial comparing the efficacy and safeaty of asenapine with olanzapnie in stable subjects with predominant, persistent negative symptoms of schizophrenia.
116.
Plough Schering. 2006. (Study 25517) Long-term assessment of asenapine versus olanzapine in patients with schizophrenia or schizoaffective disorder. [PubMed: 20205074]
117.
Plough Schering. 2006. (Study 041022) A multicenter, randomized, double-blind, flexible-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine positive control in subjects with an acute exacerbation of schizophrenia.
118.
Plough Schering. 2006. (Study 041021) A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine positive control in subjects with an acute exacerbation of schizophrenia.
119.
Plough Schering. 2007. (Study 25544) A multicenter, double-blind, flexible-dose, 6-month extension trial comparing the efficacy and safety of asenapine with olanzapine who compelted protocol 25543.
120.
Smith RC, Lindenmayer J-P, Davis JM, et al. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. J Clin Psychiatry. 2009 Nov;70(11):1501–1513. [PubMed: 19814947]
121.
Suzuki T, Uchida H, Watanabe K, et al. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology (Berl) 2007 Dec;195(2):285–295. [PubMed: 17701027]
122.
Tschoner A, Engl J, Rettenbacher M, et al. Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. Pharmacopsychiatry. 2009 Jan;42(1):29–34. [PubMed: 19153944]
123.
van Nimwegen L, de Haan L, van Beveren N, Laan W, van den Brink W, Linszen D. Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis. J Clin Psychopharmacol. 2008 Apr;28(2):214–218. [PubMed: 18344733]
124.
Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry. 2009 Oct;70(10):1397–1406. [PubMed: 19906343]
125.
Zimbroff D, Warrington L, Loebel A, Yang R, Siu C. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol. 2007 Nov;22(6):363–370. [PubMed: 17917555]
126.
Blonde L, Kan HJ, Gutterman EM, et al. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. J Clin Psychiatry. 2008 May;69(5):741–748. [PubMed: 18435564]
127.
Hanssens L, L’Italien G, Loze J-Y, Marcus RN, Pans M, Kerselaers W. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913) BMC Psychiatry. 2008;8:95. [PMC free article: PMC2637262] [PubMed: 19102734]
128.
Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. European Psychiatry: the Journal of the Association of European Psychiatrists. 2007 Oct;22(7):433–443. [PubMed: 17555947]
129.
Taylor D, Hanssens L, Loze J-Y, Pans M, L’Italien G, Marcus RN. Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study. European Psychiatry: the Journal of the Association of European Psychiatrists. 2008 Aug;23(5):336–343. [PubMed: 18423987]
130.
Stroup TS, Lieberman JA, McEvoy JP, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res. 2009 Jan;107(1):1–12. [PMC free article: PMC2675163] [PubMed: 19027269]
131.
Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry. 2007 Sep–Oct;15(5):245–258. [PubMed: 17924259]
132.
Teich J. The CATIE study. Am J Psychiatry. 2006 Mar;163(3):554–555. author reply 555–556. [PubMed: 16513894]
133.
Weiden PJ. Discontinuing and switching antipsychotic medications: Understanding the CATIE schizophrenia trial. J Clin Psychiatry. 2007;68(Suppl1):12–19. [PubMed: 17286523]
134.
Barak Y, Mirecki I, Knobler HY, Natan Z, Aizenberg D. Suicidality and second generation antipsychotics in schizophrenia patients: A case-controlled retrospective study during a 5-year period. Psychopharmacology (Berl) 2004 Sep;175(2):215–219. [PubMed: 14760515]
135.
Lucey JV, Libretto SE. Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis. Ir J Med Sci. 2003;172(4):195–201. [PubMed: 15029989]
136.
Procyshyn RM, Zerjav S. Drug utilization patterns and outcomes associated with inhospital treatment with risperidone or olanzapine. Clin Ther. 1998;20(6):1203–1217. [PubMed: 9916613]
137.
Snaterse M, Welch R. A retrospective, naturalistic review comparing clinical outcomes of in-hospital treatment with risperidone and olanzapine. Clinical Drug Investigation. 2000;20(3):159–164.
138.
Taylor DM, Wright T, Libretto SE. Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia UKIG. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. J Clin Psychiatry. 2003;64(5):589–597. [PubMed: 12755664]
139.
Zhao Z. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. Manag Care Interface. 2002;15(2):75–81. [PubMed: 11875967]
140.
Advokat C, Dixon D, Schneider J, Comaty JE Jr. Comparison of risperidone and olanzapine as used under “real-world” conditions in a state psychiatric hospital. Prog Neuropsychopharmacol Biol Psychiatry. 2004 May;28(3):487–495. [PubMed: 15093956]
141.
Bond GR, Kim HW, Meyer PS, et al. Response to vocational rehabilitation during treatment with first- or second-generation antipsychotics. Psychiatr Serv. 2004;55(1):59–66. [PubMed: 14699202]
142.
de Haan L, Beuk N, Hoogenboom B, Dingemans P, Linszen D. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. J Clin Psychiatry. 2002;63(2):104–107. [PubMed: 11874209]
143.
Dinakar HS, Sobel RN, Bopp JH, Daniels A, Mauro S. Efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among long-stay state hospital patients. Psychiatr Serv. 2002;53(6):755–757. [PubMed: 12045315]
144.
Garcia-Cabeza I, Gomez JC, Sacristan JA, Edgell E, Gonzalez de Chavez M. Subjective response to antipsychotic treatment and compliance in schizophrenia. BMC Psychiatry. 2001;1(1):7. [PMC free article: PMC65550] [PubMed: 11835695]
145.
Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O. Glucose intolerance with atypical antipsychotics. Drug Saf. 2002;25:1107–1116. [PubMed: 12452735]
146.
Ho BC, Miller D, Nopoulos P, Andreasen NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry. 1999;60(10):658–663. [PubMed: 10549681]
147.
Kasper S, Rosillon D, Duchesne I. Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): Efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol. 2001;16(4):179–187. [PubMed: 11459331]
148.
Koro CE, Fedder DO, L’Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002;59(11):1021–1026. [PubMed: 12418935]
149.
Madhusoodanan S, Suresh P, Brenner R, Pillai R. Experience with the atypical antipsychotics - Risperidone and olanzapine in the elderly. Ann Clin Psychiatry. 1999;11(3):113–118. [PubMed: 10482120]
150.
Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63(5):425–433. [PubMed: 12019668]
151.
Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients; subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50(1–2):79–88. [PubMed: 11378316]
152.
Verma S, Orengo CA, Kunik ME, Hale D, Molinari VA. Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients. Int J Geriatr Psychiatry. 2001;16(2):223–227. [PubMed: 11241729]
153.
Voruganti L, Cortese L, Ouyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and new antipsychotic drugs with reference to their subjective tolerability, side effect profile and impact on quality of life. Schizophr Res. 2000;43(2–3):135–145. [PubMed: 10858632]
154.
Voruganti L, Cortese L, Owyeumi L, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res. 2002;57(2–3):201–208. [PubMed: 12223251]
155.
Dolder CR, Lacro JP, Dunn LB, Jeste D. American Journal of Psychiatry. 1. Vol. 159. Jan, 2002. 2002. Antipsychotic medication adherence: Is there a difference between typical and atypical agents? pp. 103–108. [PubMed: 11772697]
156.
Joyce AT, Harrison DJ, Loebel AD, Ollendorf DA. Impact of atypical antipsychotics on outcomes of care in schizophrenia. Am J Manag Care. 2005 Sep;11(8 Suppl):S254–261. [PubMed: 16180964]
157.
Kopala LC, Good KP, Milliken H, et al. Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2 year outcomes. Schizophr Res. 2006 Jan 1;81(1):29–39. [PubMed: 16263246]
158.
Pelagotti F, et al. Dropout rates with olanzapine or risperidone: a multi-centre observational study. Eur J Clin Pharmacol. 2003;59:905–909. [PubMed: 14685800]
159.
Remington G, Khramov I. Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2001 Feb;25(2):363–369. [PubMed: 11294482]
160.
Soholm B, Lublin H. Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study. Acta Psychiatr Scand. 2003 May;107(5):344–350. [PubMed: 12752030]
161.
Taylor M, Turner M, Watt L, Brown D, Martin M, Fraser K. Atypical anti-psychotics in the real world--a naturalistic comparative outcome study. Scott Med J. 2005 Aug;50(3):102–106. [PubMed: 16163994]
162.
Haro JM, Novick D, Suarez D, et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol. 2006 Dec;26(6):571–578. [PubMed: 17110813]
163.
Dossenbach M, Dyachkova Y, Pirildar S, et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. European Psychiatry: the Journal of the Association of European Psychiatrists. 2006 Jun;21(4):251–258. [PubMed: 16530390]
164.
Ascher-Svanum H, et al. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gern Hosp Psychiatry. 2004;3:11. [PMC free article: PMC428579] [PubMed: 15175112]
165.
Cooper D, et al. Ambulatory Use of Olanzapine and Risperidone: A Population-Based Study on Persistence and the Use of Concomitant Therapy in the Treatment of Schizophrenia. Canadian Journal of Psychiatry. 2005 Dec;50(14):901–908. [PubMed: 16494259]
166.
Cooper D, Moisan J, Gregoire J-P. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry. 2007 Jun;68(6):818–825. [PubMed: 17592904]
167.
Gianfrancesco F, Rajagopalan K. Treatment adherence with antipsychotics among patients with bipolar or manic disorder. J Clin Psychiatry. 2006a;67(2):222–232. [PubMed: 16566617]
168.
Gianfrancesco F, Rajagopalan K, Wang RH. Hospitalization risks in the treatment of schizophrenia: comparison of antipsychotic medications. J Clin Psychopharmacol. 2006b;26(4):401–404. [PubMed: 16855459]
169.
Gibson JP, al E. The Impact of Olanzapine, Risperidone, or Haloperidol on the Cost of Schizophrenia Care in a Medicaid Population. Value in Health. 2004;7(1):22–35. [PubMed: 14720128]
170.
Hodgson DM, et al. The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire. Human Psychopharmacology. 2005 Jan;20(2):141–147. [PubMed: 15651052]
171.
Lambert M, Conus P, Schimmelmann B, et al. Pharmacopsychiatry. 5. Vol. 38. Sep, 2005. 2005. Comparison of Olanzapine and Risperidone in 367 First-Episode Patients with Non-Affective or Affective Psychosis: Results of an Open Retrospective Medical Record Study; pp. 206–213. [PubMed: 16189747]
172.
Lin C-H, Lin S-C, Chen M-C, Wang S-Y. Comparison of time to rehospitalization among schizophrenic patients discharged on typical antipsychotics, clozapine or risperidone. Journal of the Chinese Medical Association: JCMA. 2006 Jun;69(6):264–269. [PubMed: 16863012]
173.
Malla A, et al. A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition. Psychiatry Res. 2004;129:159–169. [PubMed: 15590043]
174.
Montes JM, Ciudad A, Gascon J, Gomez JC. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: A naturalistic study. Progress in Neuro Psychopharmacology & Biological Psychiatry. 2003;27(4):667–674. [PubMed: 12787855]
175.
Rascati KL, et al. Olanzapine versus Risperidone in the Treatment of Schizophrenia: A Comparison of Costs among Texas Medicaid Recipients. Pharmacoeconomics. 2003;21(10):683–697. [PubMed: 12828491]
176.
Ren X, et al. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents. J Clin Pharm Ther. 2006;31(1):57–65. [PubMed: 16476121]
177.
Strous RD, Kupchik M, Roitman S, et al. Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. Human Psychopharmacology. 2006 Jun;21(4):235–243. [PubMed: 16783815]
178.
Swanson J, et al. Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. J Clin Psychiatry. 2004;65:1666–1673. [PubMed: 15641872]
179.
Tiihonen J, Wahlbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ British Medical Journal. 2006 2006 Jul;333(7561):224–227. [PMC free article: PMC1523484] [PubMed: 16825203]
180.
Zhao Z, et al. Medication Treatment Patterns following Initiation on Olanzapine versus Risperidone. Clin Drug Invest. 2002;22(11):741–749.
181.
Akkaya C, Sarandol A, Cangur S, Kirli S. Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting. Human Psychopharmacology. 2007 Dec;22(8):515–528. [PubMed: 17868197]
182.
Alonso J, Croudace T, Brown J, et al. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study. Value in Health. 2009 Jun;12(4):536–543. [PubMed: 19900255]
183.
Ascher-Svanum, Nyhuis AW, Faries D, Kinon BJ, Heiler L. Treatment Discontinuation Following Randomization to Open-Label Olanzapine, Risperidone or Typical Antipsychotics During a One-Year Treatment for Schizophrenia (HGGD) Clinical Schizophrenia and Related Psychoses. 2008;2(3):226–234.
184.
Castro APWd, Elkis H. Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine. Revista Brasileira de Psiquiatria. 2007 Sep;29(3):207–212. [PubMed: 17891257]
185.
Chen L, McCombs JS, Park J. Duration of antipsychotic drug therapy in real-world practice: a comparison with CATIE trial results. Value in Health. 2008 May–Jun;11(3):487–496. [PubMed: 18489672]
186.
Chen L, McCombs JS, Park J. The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia. Value in Health. 2008 Jan–Feb;11(1):34–43. [PubMed: 18237358]
187.
Citrome L, Jaffe A, Levine J, Allingham B, Robinson J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv. 2004 Sep;55(9):1006–1013. [PubMed: 15345760]
188.
Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009 Oct 28;302(16):1765–1773. [PMC free article: PMC3055794] [PubMed: 19861668]
189.
De Hert M, Schreurs V, Sweers K, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008 Apr;101(1–3):295–303. [PubMed: 18299188]
190.
Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ. Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia. Curr Med Res Opin. 2008 May;24(5):1399–1405. [PubMed: 18397549]
191.
Fraguas D, Merchan-Naranjo J, Laita P, et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry. 2008 Jul;69(7):1166–1175. [PubMed: 18588363]
192.
Haro JM, Novick D, Suarez D, Ochoa S, Roca M. Predictors of the course of illness in outpatients with schizophrenia: a prospective three year study. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;32(5):1287–1292. [PubMed: 18502012]
193.
Haukka J, Tiihonen J, Harkanen T, Lonnqvist J. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiology & Drug Safety. 2008 Jul;17(7):686–696. [PubMed: 18327869]
194.
Herceg M, Jukic V, Vidovic D, et al. Two-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: retrospective cohort study. Croat Med J. 2008 Apr;49(2):215–223. [PMC free article: PMC2359893] [PubMed: 18461677]
195.
Hrdlicka M, Zedkova I, Blatny M, Urbanek T. Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study. Neuroendocrinology Letters. 2009;30(2):256–261. [PubMed: 19675512]
196.
Karagianis J, Williams R, Davis L, et al. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia. Curr Med Res Opin. 2009 Sep;25(9):2121–2132. [PubMed: 19601707]
197.
Kilzieh N, Todd-Stenberg JA, Kennedy A, Wood AE, Tapp AM. Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting. J Clin Psychopharmacol. 2008 Feb;28(1):74–77. [PubMed: 18204345]
198.
Kim B, Lee S-H, Choi TK, et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;32(5):1231–1235. [PubMed: 18442879]
199.
Kim JH, Kim D, Marder SR. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15;32(4):984–988. [PubMed: 18262321]
200.
Lindstrom E, Eberhard J, Levander S. Five-year follow-up during antipsychotic treatment: efficacy, safety, functional and social outcome. Acta Psychiatrica Scandinavica, Supplementum. 2007;(435):5–16. [PubMed: 17953521]
201.
Maskasame S, Krisanaprakornkit T, Khiewyoo J. The incidence of clozapine-induced leukopenia in patients with schizophrenia at Srinagarind Hospital. J Med Assoc Thai. 2007 Oct;90(10):2175–2180. [PubMed: 18041439]
202.
Medved V, Kuzman MR, Jovanovic N, Grubisin J, Kuzman T. Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up. J Psychopharmacol (Oxf) 2009 Nov;23(8):915–922. [PubMed: 18635691]
203.
Mohamed S, Rosenheck R, Harpaz-Rotem I, Leslie D, Sernyak MJ. Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia. Psychiatr Q. 2009 Dec;80(4):241–249. [PubMed: 19768543]
204.
Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res. 2008 Jan;98(1–3):8–15. [PubMed: 17596914]
205.
Munro J, O’Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12760 clozapine recipients in the UK and Ireland: Beyond pharmacovigilance. Br J Psychiatry. 1999;175:576–580. [PubMed: 10789357]
206.
Olivares JM, Peuskens J, Pecenak J, et al. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin. 2009 Sep;25(9):2197–2206. [PubMed: 19604073]
207.
Perez V, Canas F, Tafalla M, Group TS. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. Int Clin Psychopharmacol. 2008 May;23(3):138–149. [PubMed: 18408528]
208.
Peuskens J, Gillain B, De Graeve D, Van Vleymen B, Albert A. Belgian schizophrenia outcome survey --Results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. European Psychiatry. 2009;24(3):154–163. [PubMed: 19118983]
209.
Ray W, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225–235. [PMC free article: PMC2713724] [PubMed: 19144938]
210.
Shajahan P, Keith S, Majjiga C, et al. Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study. J Clin Psychiatry. 2009 May;70(5):692–698. [PubMed: 19284930]
211.
Tadger S, Melamed Y. Weight gain due to long term antipsychotic treatment of persistent mental disorders. Psychiatria Danubina. 2008 Mar;20(1):37–41. [PubMed: 18376329]
212.
Taylor DM, Douglas-Hall P, Olofinjana B, Whiskey E, Thomas A. Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. Br J Psychiatry. 2009 Feb;194(2):165–167. [PubMed: 19182180]
213.
Taylor M, Shajahan P, Lawrie SM. Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. J Clin Psychiatry. 2008 Feb;69(2):240–245. [PubMed: 18363452]
214.
Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study) Lancet. 2009 Aug 22;374(9690):620–627. [PubMed: 19595447]
215.
van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2008 Mar;69(3):472–479. [PubMed: 18348593]
216.
Yu AP, Atanasov P, Ben-Hamadi R, Birnbaum H, Stensland MD, Philips G. Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population. Value in Health. 2009 Jul–Aug;12(5):708–715. [PubMed: 19508658]
217.
Zhang XY, Tan YL, Zhou DF, et al. Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J Psychiatr Res. 2007 Dec;41(12):997–1004. [PubMed: 17095017]
218.
Dossenbach M, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Journal Clinical Psychiatry. 2005 Aug;66:1021–1030. [PubMed: 16086618]
219.
Haro J, et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan- European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatrica Scandinavia. 2005;111:220–231. [PubMed: 15701107]
220.
Glick ID, Zaninelli R, Hsu C, et al. Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior. J Clin Psychiatry. 2004;65(5):679–685. [PubMed: 15163255]
221.
Arato M, O’Connor R, Meltzer HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17(5):207–215. [PubMed: 12177583]
222.
Peuskins J, Trivedi J, Malyarov S, et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. Psychiatry. 2007;4(11):34–50. [PMC free article: PMC2860517] [PubMed: 20428302]
223.
Plough Schering. 2008. (Study 7501012) A randomized, placebo-controlled, double-blind trial of asenapine in the prevention of relapse after long-term treatment of schizophrenia.
224.
Karagianis J, Rosenbluth M, Tohen M, et al. Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Curr Med Res Opin. 2007;23(10):2551–2557. [PubMed: 17845743]
225.
Gianfrancesco F, Wang RH, Pesa J, Rajagopalan K. Hospitalisation risks in the treatment of schizophrenia in a Medicaid population: comparison of antipsychotic medications. Int J Clin Pract. 2006 Nov;60(11):1419–1424. [PubMed: 17073838]
226.
Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, Ratner Y. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol. 2004;24(6):582–591. [PubMed: 15538118]
227.
Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry. 2007 Mar;164(3):428–436. [PubMed: 17329467]
228.
Rosenheck RA, Davis S, Covell N, et al. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res. 2009 Jan;107(1):22–29. [PubMed: 18993031]
229.
Gasquet I, et al. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int Clin Psychopharmacol. 2005 Jul;20:199–205. [PubMed: 15933480]
230.
Silva de Lima M, de Jesus Mari J, Breier A, Maria Costa A, Ponde de Sena E, Hotopf M. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. J Clin Psychiatry. 2005 Jul;66(7):831–838. [PubMed: 16013897]
231.
Mahmoud R, Engelhart L, Janagap C, Oster G, Ollendorf D. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care. Clinical Drug Investigation. 2004;24(5):275–286. [PubMed: 17503889]
232.
Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM Jr. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res. 1999;8(5):417–426. [PubMed: 10474283]
233.
Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia: A Randomized Controlled Trial. Journal of the American Medical Association. 2003;290(20):2693–2702. [PubMed: 14645311]
234.
Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry. 2004;65(4):531–536. [PubMed: 15119916]
235.
Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125–1132. [PubMed: 12777271]
236.
Ciudad A, Olivares JM, Bousono M, Gomez JC, Alvarez E. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1515–1522. [PubMed: 16820255]
237.
Harvey PD, Patterson TL, Potter LS, Zhong K, Brecher M. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry. 2006 Nov;163(11):1918–1925. [PubMed: 17074943]
238.
Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry. 2008 May;69(5):817–829. [PubMed: 18466043]
239.
Resnick SG, Rosenheck RA, Canive JM, et al. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. J Behav Health Serv Res. 2008 Apr;35(2):215–225. [PubMed: 18246429]
240.
Korb FA, Trzebiatowska I, Janikova E, et al. The Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study: Baseline clinical and functional characteristics and antipsychotic use of patterns in the Central and Eastern Europe (CEE) region. Psychiatria Danubina. 2003;15(3–4):163–174. [PubMed: 19114924]
241.
Novick D, Haro JM, Suarez D, Vieta E, Naber D. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 2009 Mar;108(1–3):223–230. [PubMed: 19070991]
242.
Kinon BJ, Noordsy DL, Liu-Seifert H, Gulliver AH, Ascher-Svanum H, Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol. 2006b Oct;26(5):453–461. [PubMed: 16974184]
243.
Gomez JC, Sacristan JA, Hernandez J, et al. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. J Clin Psychiatry. 2000;61(5):335–343. [PubMed: 10847307]
244.
Bitter I, Czobor P, Dossenbach M, Volavka J. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: A prospective naturalistic study (IC-SOHO) European Psychiatry. 2005 2005 Aug;20:5–6. 403–408. [PubMed: 16084068]
245.
Swanson JW, Swartz MS, Van Dorn RA, et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry. 2008 Jul;193(1):37–43. [PMC free article: PMC2801826] [PubMed: 18700216]
246.
Citrome L, Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract. 2006 Aug;60(8):933–940. [PubMed: 16893436]
247.
Haro J, et al. Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. European Psychiatry. 2006;21:41–47. [PubMed: 16414249]
248.
Chen C-H, Chiu C-C, Huang M-C, Wu T-H, Liu H-C, Lu M-L. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15;32(4):925–931. [PubMed: 18082302]
249.
Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang R-H. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Res. 2006 Nov 15;144(2–3):177–189. [PubMed: 17010448]
250.
Klieser E, Kinzler E. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double-blind, randomised trial. Clinical report. 1991;18:129–137. [PubMed: 7509495]
251.
Mori K, Nagao M, Yamashita H, Morinobu S, Yamawaki S. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):659–665. [PubMed: 15276691]
252.
Volavka J, Czobor P, Nolan K, et al. Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol. J Clin Psychopharmacol. 2004 Apr;24(2):225–228. [PubMed: 15206671]
253.
Kraus JE, Sheitman BB, Cook A, Reviere R, Lieberman JA. Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. J Clin Psychiatry. 2005 Dec;66(12):1564–1568. [PubMed: 16401158]
254.
Mladsi DM, Grogg AL, Irish WD, et al. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. Curr Med Res Opin. 2004;20(12):1883–1893. [PubMed: 15701206]
255.
Snaterse M, Welch R. A retrospective and naturalistic review comparing outcomes of patients treated with olanzapine or risperidone. Journal of the European College of Neuropsychopharmacology. 1999;9(sUPPL 5):S260.
256.
Kinon BJ, Ahl J, Rotelli MD, McMullen E. Efficacy of accelerated dose titrationof olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. Am J Emerg Med. 2004;22(3):181–186. [PubMed: 15138953]
257.
Leucht S, Kane JM. Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia. J Clin Psychiatry. 2006 Nov;67(11):1813–1814. [PubMed: 17196063]
258.
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005 Nov 15;79(2–3):231–238. [PubMed: 15982856]
259.
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry. 1988;45(9):789–796. [PubMed: 3046553]
260.
Bondolfi G, Baumann P, Patris M, May J, Billeter U, Dufour H. A Randomized Double-bind Trial of Risperidone Versus Clozapine for Treatment-resistant Chronic Schizophrenia. Paper presented at: 8th European College of Neuropsychopharmacology Congress; 1995; Venice, Italy.
261.
Tollefson GD, Andersen SW. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? [Review] [45 refs] J Clin Psychiatry. 1999b;60(5):23–29. [PubMed: 10192404]
262.
AstraZeneca. 2008. (D1441C00112) A 6-week, International, multicenter, randomized, double-blind, parallel-group, placebo-controlled, phase IIIb study of the efficacy and safety of quetiapine fumarate (SEROQUEL TM) Immediate-release tablets in daily doses of 400 mg and 800 mg compared with placebo in the treatment of adolescents with schizophrenia.
263.
Bai YM, Chen TT, Wu B, et al. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry. 2006 Jul;39(4):135–141. [PubMed: 16900609]
264.
Center for Drug Evaluation and Research. FDA Statistical Review of Iloperidone: New Drug Application. 2007.
265.
Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S4–11. [PubMed: 18334911]
266.
Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S12–19. [PubMed: 18334908]
267.
Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S29–35. [PubMed: 18334910]
268.
Williams R, Kopala L, Malla A, Smith G, Love L, Balshaw R. Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia. Acta Psychiatrica Scandinavica, Supplementum. 2006;(430):12–21. [PubMed: 16542321]
269.
Vanelli M, Burstein P, Cramer J. Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain. Psychiatr Serv. 2001 Sep;52(9):1248–1250. [PubMed: 11533402]
270.
Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004;30:255–264. [PubMed: 15279044]
271.
Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J, Group SS. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry. 2005 Sep;66(9):1130–1133. [PubMed: 16187770]
272.
Swanson JW, Swartz MS, Elbogen EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull. 2004;30(1):3–20. [PubMed: 15176758]
273.
Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis. Schizophrenia Research. 2007 2007 Jul;93:1–3. 90–98. [PMC free article: PMC2100420] [PubMed: 17478082]
274.
Opolka J, et al. Role of Ethnicity in Predicting Antipsychotic Medication Adherence. Ann Pharmacother. 2003;37:625–630. [PubMed: 12708934]
275.
Novak-Grubic V. Treatment compliance in first-episode schizophrenia. Psychiatric Services. 1999 1999 Jul;50(7):970–971. [PubMed: 10402627]
276.
McGrath BM, Tempier R. Patients’ Opinions of Olanzapine and Risperidone Following Long-term Treatment: Results from a Cross-sectional Survey. Pharmacopsychiatry. 2005 2005 Jul;38(4):147–157. [PubMed: 16025416]
277.
Lindstrom LH. A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period. Psychopharmacology. 1989;1989;99(Suppl):84–86. [PubMed: 2813670]
278.
Kim J-H, Kim S-Y, Ahn YM, Kim YS. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia Progress. Neuro-Psychopharmacology & Biological Psychiatry. 2006 2006 Mar;30(2):301–305. [PubMed: 16309807]
279.
Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol. 1998;8(3):151–159. [PubMed: 9853689]
280.
Kearns AE, Goff DC, Hayden DL, Daniels GH. Risperidone-associated hyperprolactinemia. Endocrine Practice. 2000 Nov–Dec;6(6):425–429. [PubMed: 11155212]
281.
Honigfeld G. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv. 1996;47(1):52–56. [PubMed: 8925346]
282.
Hassan M, Madhavan SS, Kalsekar ID, et al. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder. Ann Pharmacother. 2007 Nov;41(11):1812–1818. [PubMed: 17925501]
283.
Han C, Lee B-H, Kim Y-K, et al. Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics. Primary Care & Community Psychiatry. 2005;10(3):2005, 119–124.
284.
Gilmer T, Dolder C, Lacro J. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692–699. [PubMed: 15056516]
285.
Gaszner P, Makkos Z. Clozapine maintenance therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004 May;28(3):465–469. [PubMed: 15093952]
286.
Ernst C, Goldberg JF. Antisuicide properties of psychotropic drugs: A critical review. Harv Rev Psychiatry. 2004 Jan–Feb;12(1):14–41. [PubMed: 14965852]
287.
Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry. 2004;65(3):354–360. [PubMed: 15096075]
288.
Coley KC, Carter CS, DaPos SV, Maxwell R, Wilson JW, Branch RA. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. J Clin Psychiatry. 1999 Dec;60(12):850–856. [PubMed: 10665632]
289.
Buckman RW, Malan RD. Clozapine for refractory schizophrenia: the Illinois experience. J Clin Psychiatry. 1999;60(Suppl 1):18–22. discussion 28–30. [PubMed: 10037166]
290.
Ascher-Svanum H, Zhu B, Faries D, Lacro J, Dolder C. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient, preferences and adherence. 2008 [PMC free article: PMC2770396] [PubMed: 19920946]
291.
Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453–460. [PubMed: 16649833]
292.
Al-Zakwani IS, Barron JJ, Bullano MF, Arcona S, Drury CJ, Cockerham TR. Analysis of healthcare utilization patterns and adherence in patients receiving typicaland atypical antipsychotic medications. Curr Med Res Opin. 2003;19(7):619–626. [PubMed: 14606985]
293.
Kahn RS. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. World Psychiatry. 2009;8(Suppl 1):44–45.
294.
Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008 Mar 29;371(9618):1085–1097. [PubMed: 18374841]
295.
Kahn RS, Schulz SC, Palazov VD, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007 Jun;68(6):832–842. [PubMed: 17592906]
296.
Lauriello J, McEvoy JP, Rodriguez S, Bossie CA, Lasser RA. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophr Res. 2005 Jan;72(2–3):249–258. [PubMed: 15560969]
297.
Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 2006 Oct;188(3):281–292. [PubMed: 16953381]
298.
Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007 Jan;68(1):111–119. [PubMed: 17284138]
299.
Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59(5):441–448. [PubMed: 11982448]
300.
Wright P, Lindborg SR, Birkett M, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie. 2003;48(11):716–721. [PubMed: 14733451]
301.
Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001;158(7):1149–1151. [PubMed: 11431240]
302.
Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry. 2000;61(12):933–941. [PubMed: 11206599]
303.
Wright P, Meehan K, Birkett M, et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther. 2003;25(5):1420–1428. [PubMed: 12867218]
304.
Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry. 2008 Oct;193(4):279–288. [PMC free article: PMC2801816] [PubMed: 18827289]
305.
Bender S, Dittmann-Balcar A, Schall U, et al. Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. International Journal of Neuropsychopharmacology. 2006 Apr;9(2):135–145. [PubMed: 16174427]
306.
Purdon SE, Woodward N, Lindborg SR, Stip E. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology (Berl) 2003;169(3–4):390–397. [PubMed: 12827347]
307.
Alvarez E, Baron F, Perez-Blanco J, Soriano DPJ, Masip C, Perez-Sola V. Ten years’ experience with clozapine in treatment-resistant schizophrenic patients: Factors indicating the therapeutic response. European Psychiatry: the Journal of the Association of European Psychiatrists. 1997;12(SUPPL 5):343S–346S. [PubMed: 19698589]
308.
Schillevoort I, de Boer A, Herings RM, Roos RA, Jansen PA, Leufkens HG. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Ann Pharmacother. 2001;35(12):1517–1522. [PubMed: 11793611]
309.
Heinrich K, Klieser E, Lehmann E, Kinzler E, Hruschka H. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18(1):129–137. [PubMed: 7509495]
310.
Heinrich K, Klieser E, Lehmann E, Kinzler E. Experimental comparison of the efficacy and compatibility of clozapine and risperidone in acute schizophrenia. Clin Neuropharmacol. 1992;15(Suppl 1;Pt B):375B.
311.
Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry. 1998;59(2):69–75. [PubMed: 9501888]
312.
Mullen J, Reinstein M, Bari M, Ginsberg L, Sander N. Quetiapine and risperidone in outpatients with psychotic disorders: results of the QUEST trial. Eur Neuropsychopharmacol. 1999;9(Suppl 5):S267.
313.
Addington DE, Labelle A, Kulkarni J, Johnson G, Loebel A, Mandel FS. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie. 2009 Jan;54(1):46–54. [PubMed: 19175979]
314.
Simpson GM, Loebel A, Warrington L, Yang R. Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder: Results of a double-blind, six-week study, with a six-month, double-blind, continuation phase. In: Cummings Jeffrey L., editor. 2006.
315.
Nussbaum AM, Stroup TS. Oral paliperidone for schizophrenia. Cochrane Database of Systematic Reviews. 2009(4) [PubMed: 22696377]
316.
Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. J Clin Psychiatry. 2009 Mar;70(3):318–325. [PubMed: 19192469]
317.
Czobor P, Volavka J, Sheitman B, et al. Antipsychotic-induced weight gain and therapeutic response: A differential association. J Clin Psychopharmacol. 2002 Jun;22(3):244–251. [PubMed: 12006893]
318.
Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry. 2008 Jan;16(1):31–43. [PubMed: 18165460]
319.
Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160(2):290–296. [PubMed: 12562575]
320.
Bobes J, Rejas J, Garcia-Garcia M, et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: Results of the EIRE study. Schizophr Res. 2003;62(1–2):77–88. [PubMed: 12765747]
321.
Ganguli R, Brar JS, Ayrton Z. Weight gain over 4 months in schizophrenia patients: A comparison of olanzapine and risperidone. Schizophr Res. 2001;49(3):261–267. [PubMed: 11356587]
322.
McIntyre RS, Trakas K, Lin D, et al. Risk of Weight Gain Associated with Antipsychotic Treatment: Results from the Canadian National Outcomes Measurement Study in Schizophrenia. Canadian Journal of Psychiatry Revue Canadienne de Psychiatrie. 2003;48(10):689–694. [PubMed: 14674052]
323.
Dossenbach M, et al. Effectiveness of Antipsychotic Treatments for Schizophrenia: Interim 6-Month Analysis From a Prospective Observational Study (IC-SOHO) Comparing Olanzapine, Quetiapine, Risperidone and Haloperidol. Journal Clinical Psychiatry. 2004;65(3):312–321. [PubMed: 15096069]
324.
Gasquet I, Haro JM, Tcherny-Lessenot S, Chartier F, Lepine J-P. Remission in the outpatient care of schizophrenia: 3-year results from the Schizophrenia Outpatients Health Outcomes (SOHO) study in France. European Psychiatry: the Journal of the Association of European Psychiatrists. 2008 Oct;23(7):491–496. [PubMed: 18573640]
325.
Novick D, Haro JM, Perrin E, Suarez D, Texeira JM. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol. 2009 Aug;19(8):542–550. [PubMed: 19500949]
326.
Lee P, Kim CE, Kim CY, et al. Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. International Journal of Psychiatry in Clinical Practice. 2008;12(3):215–227. [PubMed: 24931661]
327.
Su KP, Wu PL, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology (Berl) 2005;183(3):383–386. [PubMed: 16240162]
328.
de Haan L, van Amelsvoort T, Rosien K, Linszen D. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology (Berl) 2004 Sep;175(3):389–390. [PubMed: 15322727]
329.
Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686–1696. [PubMed: 10553730]
330.
Kryzhanovskaya LA, Robertson-Plouch CK, Xu W, Carlson JL, Merida KM, Dittmann RW. The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry. 2009 Feb;70(2):247–258. [PubMed: 19210948]
331.
Lambert BL, Chang K-Y, Tafesse E, Carson W. Association Between Antipsychotic Treatment and Hyperlipidemia Among California Medicaid Patients With Schizophrenia. J Clin Psychopharmacol. 2005 Feb;25(1):12–18. [PubMed: 15643095]
332.
Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology. 2006 Apr;31(3):340–346. [PubMed: 16198059]
333.
Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry. 2005 Jan;66(1):80–84. [PubMed: 15669892]
334.
Conley R, Kelly D, Nelson ME, et al. Risperidone and quetiapine vs fluphenazine in treatment resistant schizophrenia. 42nd Annual Meeting of the American College of Neuro Psychopharmacology; December 7–11, 2003; 2003.
335.
Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol. 2006 Oct 1;164(7):672–681. [PubMed: 16943266]
336.
Feldman PD, Kaiser CJ, Kennedy JS, et al. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. J Clin Psychiatry. 2003;64(9):998–1004. [PubMed: 14628974]
337.
Ciliberto N, Bossie CA, Urioste R, Lasser RA. Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol. 2005 Jul;20(4):207–212. [PubMed: 15933481]
338.
Usall J, Suarez D, Haro JM, Group SS. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res. 2007 Dec 3;153(3):225–231. [PubMed: 17681611]
339.
Swartz MS, Wagner HR, Swanson JW, et al. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr Res. 2008 Mar;100(1–3):39–52. [PubMed: 18191383]
340.
Kinon B. Improvement of comorbid depression with olanzapine versus ziprasidone treatment in patients with schizophrenia or schizoaffective disorder. Paper presented at: Eleventh Biennial Winter Workshop on Schizophrenia; Feb 7–14, 2004; Davos, Switzerland.
341.
Lawson WB, Herman BK, Loebel A, Lazariciu I, Malik M. Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies. Cns Spectrums. 2009 Sep;14(9):478–486. [PubMed: 19890230]
342.
Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran Q-V, Assuncao-Talbott S. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord. 2009 May;115(1–2):18–26. [PubMed: 19230981]
343.
Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry. 2002;63(12):1156–1163. [PubMed: 12523876]
344.
Sutton VK, Street JS, Kennedy JS, Feldman PD, Breier A. Superiority of olanzapine over risperidone in the control of negative symptoms of schizophrenia and related psychotic disorders in older patients. Eur Neuropsychopharmacol. 2001;11:276.
345.
Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, Carothers J, Turkoz I, Schooler N. A randomized, double-blind, placebo-controlled study of paliperidone ER in the treatment of subjects with schizoaffective disorder. Paper presented at: International Congress on Schizophrenia Research; Mar 28– April 1, 2009; San Diego, CA.
346.
McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disorders. 2009 Dec;11(8):815–826. [PubMed: 19832806]
347.
Plough Schering. 2007. (Study 7501007) A double-blind, 40-week continuation study evaluating the safety of asenapine and olanzapine in the treatment of subjects with acute mania.
348.
Nejtek VA, Avila M, Chen L-A, et al. Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial. J Clin Psychiatry. 2008 Aug;69(8):1257–1266. [PubMed: 18681757]
349.
Perlis RH, Baker RW, Zarate CA Jr, et al. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry. 2006 Nov;67(11):1747–1753. [PubMed: 17196055]
350.
Harvey PD, Hassman H, Mao L, Gharabawi GM, Mahmoud RA, Engelhart LM. Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. J Clin Psychiatry. 2007 Aug;68(8):1186–1194. [PubMed: 17854242]
351.
McNeil Ortho. 2007. (NCT00309699) A randomized, double-blind, active- and placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of flexibly dosed, extended-release paliperidone compared with flexibly dosed quetiapine and placebo in the treatment of acute manic and mixed episodes associated with Bipolar I Disorder.
352.
Gianfrancesco F, Rajagopalan K, Goldberg JF. Hospitalization risks in the treatment of bipolar disorder: comparison of antipsychotic medications. Bipolar Disorders. 2007;9:252–261. [PubMed: 17430300]
353.
Zhu B, et al. Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder. Curr Med res Opinion. 2007;23(11):2805–2814. [PubMed: 17910804]
354.
Guo JJ, Keck PE Jr, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. J Clin Psychiatry. 2006 Jul;67(7):1055–1061. [PubMed: 16889448]
355.
Altamura AC, Mundo E, Dell’Osso B, Tacchini G, Buoli M, Calabrese JR. Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: a 4-year follow-up naturalistic study. J Affect Disord. 2008 Sep;110(1–2):135–141. [PubMed: 18329720]
356.
Kim E, Maclean R, Ammerman D, et al. Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis. Clin Ther. 2009 Apr;31(4):836–848. [PubMed: 19446157]
357.
Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160(9):1651–1658. [PubMed: 12944341]
358.
Keck PE, Orsulak PJ, Cutler AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord. 2009 Jan;112(1–3):36–49. [PubMed: 18835043]
359.
Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week, placebo-controlled study. J Psychopharmacol (Oxf) 2006 [PubMed: 16401666]
360.
Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry. 2009 Jan;194(1):40–48. [PubMed: 19118324]
361.
Barbini B, Scherillo P, Benedetti F, Crespi G, Colombo C, Smeraldi E. Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int Clin Psychopharmacol. 1997;12(2):109–112. [PubMed: 9219046]
362.
Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry. 2000;57(9):841–849. [PubMed: 10986547]
363.
Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry. 1999;156(5):702–709. [PubMed: 10327902]
364.
Tohen M, Vieta E, Goodwin GM, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry. 2008 Nov;69(11):1776–1789. [PubMed: 19014751]
365.
Bowden CL, Grunze H, Mullen J, et al. A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Quetiapine or Lithium as Monotherapy for Mania in Bipolar Disorder. J Clin Psychiatry. 2005 Jan;66(1):111–121. [PubMed: 15669897]
366.
McIntyre JS, et al. Quetiapine or haloperidol as monotherapy for bipolar mania---a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 2005;15:573–585. [PubMed: 16139175]
367.
AstraZeneca. 2007. (D144CC00004) A Multicenter, Double-blind, Randomized, Parallel-group, Placebo controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Sustainedrelease as Monotherapy in Adult Patients with Acute Bipolar Mania.
368.
Hirschfeld RM, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161(6):1057–1065. [PubMed: 15169694]
369.
Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania. Br J Psychiatry. 2005;187:229–334. [PubMed: 16135859]
370.
Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: A 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005 Jan;15(1):75–84. [PubMed: 15572276]
371.
Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160(4):741–748. [PubMed: 12668364]
372.
Potkin SG, Keck PE Jr, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005 Aug;25(4):301–310. [PubMed: 16012271]
373.
Vieta E, T’Joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry. 2008 Oct;165(10):1316–1325. [PubMed: 18381903]
374.
Plough Schering. 2007. (Study 7501008) A phase 3, randomized, placebo-controlled, double-blinded trial evaluating the safety and efficacy of asenapine in subjects continuing lithium or valproic acid/divalproex sodium for the treatment of an acute manic or mixed episode.
375.
Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59(1):62–69. [PubMed: 11779284]
376.
Tohen M, Bowden CL, Smulevich AB, et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry. 2008 Feb;192(2):135–143. [PubMed: 18245032]
377.
Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double blind, placebo-controlled study. Bipolar Disorders. 2004;6(3):213–223. [PubMed: 15117400]
378.
Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol. 2004 Dec;24(6):599–606. [PubMed: 15538120]
379.
Yatham LN, Vieta E, Young AH, Moller H-J, Paulsson B, Vagero M. A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. Int Clin Psychopharmacol. 2007 Jul;22(4):212–220. [PubMed: 17519644]
380.
Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159(7):1146–1154. [PubMed: 12091192]
381.
Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry. 2003;182:141–147. [PubMed: 12562742]
382.
Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007 Apr;64(4):442–455. [PubMed: 17404121]
383.
Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disorders. 2007 Sep;9(6):551–560. [PubMed: 17845269]
384.
Vieta E, Nuamah I, Lim P, et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar disorders. 2010;12(3):230–243. [PubMed: 20565430]
385.
McNeil Ortho. 2007. (NCT00299715) A randomized, double-blind, placebo-controlled, parallel-group, dose-response, multicenter study to evaluate the efficacy and safety of three fixed doses of extended-release paliperidone (3, 6, and 12 mg/day) in the treatment of subjects with acute manic and mixed episodes associated with Bipolar I Disorder.
386.
Plough Schering. 2007. (Study 7501009) A phase 3, placebo-controlled, double-blinded continuation trial evaluating the safety and efficacy of asenapine in subjects completing trial A7501008 and continuing lithium or valproic acid/divalproex sodium for the treatment of an acute manic or mixed episode.
387.
Keck PE Jr, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006 Apr;67(4):626–637. [PubMed: 16669728]
388.
Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003a;160(7):1263–1271. [PubMed: 12832240]
389.
AstraZeneca. 2008. (D1447C00144) Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate and Lithium as Monotherapy for up to 104 Weeks Maintenance Treatment of Bipolar I Disorder in Adult Patients.
390.
Suppes T, Vieta E, Liu S, Brecher M, Paulsson B, Trial I. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127) Am J Psychiatry. 2009 Apr;166(4):476–488. [PubMed: 19289454]
391.
Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126) J Affect Disord. 2008 Aug;109(3):251–263. [PubMed: 18579216]
392.
Macfadden W, Alphs L, Haskins JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disorders. 2009 Dec;11(8):827–839. [PubMed: 19922552]
393.
Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008;28(1):13–20. [PubMed: 18204335]
394.
Tohen M, Vieta E, Calabrese J, et al. Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression. Arch Gen Psychiatry. 2003;60(11):1079–1088. [PubMed: 14609883]
395.
Amsterdam JD, Shults J. Journal of Affective Disorders. 1. Vol. 87. Jul, 2005. 2005. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction; pp. 121–130. [PubMed: 15923042]
396.
McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II) J Clin Psychiatry. 2010 Feb;71(2):163–174. [PubMed: 20122366]
397.
Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I) J Clin Psychiatry. 2010 Feb;71(2):150–162. [PubMed: 20122369]
398.
Calabrese J, et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II Depression. Am J Psychiatry. 2005;162:1351–1360. [PubMed: 15994719]
399.
Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study) J Clin Psychopharmacol. 2006 Dec;26(6):600–609. [PubMed: 17110817]
400.
Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010 Feb;121(1–2):106–115. [PubMed: 19903574]
401.
AstraZeneca. 2007. (D1447C00001-EMBOLDEN I) An International, Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™, single oral 300 mg or 600 mg dose) and Lithium as Monotherapy in Adult Patients with Bipolar Depression for 8 weeks and Quetiapine in Continuation Treatment for 26 up to 52 weeks.
402.
Sanger TM, Tohen M, Vieta E, et al. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affect Disord. 2003;73(1–2):155–161. [PubMed: 12507748]
403.
Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159(6):1011–1017. [PubMed: 12042191]
404.
Suppes T, Brown E, Schuh LM, Baker RW, Tohen M. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: Post hoc analyses of 47-week data. Journal of Affective Disorders. 2005 2005 Dec;89:1–3. 69–77. [PubMed: 16253344]
405.
Zimbroff D, Vester-Blockland E, Manos G, Auby P, Pikalov AA, Oren D. Effectiveness of a single instramuscular injection of aripiprazole in patients with schizophrenia or bipolar disoder, stratified by levels of agitation. Paper presented at: 159th American Psychiatric Association Meeting; 2006; Toronto, Canada.
406.
Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001;21(4):389–397. [PubMed: 11476123]
407.
Namjoshi MA, Risser R, Shi L, Tohen M, Breier A. Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. J Affect Disord. 2004 Sep;81(3):223–229. [PubMed: 15337326]
408.
Namjoshi MA, Rajamannar G, Jacobs T, et al. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. J Affect Disord. 2002;69(1–3):109–118. [PubMed: 12103458]
409.
Thase ME. BOLDER II study of quetiapine therapy for bipolar depression. Future Neurology. 2007;2(4):373–377.
410.
McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disorders. 2009 Nov;11(7):673–686. [PubMed: 19839993]
411.
McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010 Apr;122(1–2):27–38. [PubMed: 20096936]
412.
Muzina DJ, Momah C, Eudicone JM, et al. Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. Int J Clin Pract. 2008 May;62(5):679–687. [PMC free article: PMC2324208] [PubMed: 18373615]
413.
Cookson J, Keck PE Jr, Ketter TA, Macfadden W. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. Int Clin Psychopharmacol. 2007 Mar;22(2):93–100. [PubMed: 17293709]
414.
Zimbroff DL, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol. 2007 Apr;27(2):171–176. [PubMed: 17414241]
415.
Sajatovic M, Calabrese JR, Mullen J. Quetiapine for the treatment of bipolar mania in older adults. Bipolar Disorders. 2008 Sep;10(6):662–671. [PubMed: 18837860]
416.
Biederman J, Mick E, Hammerness P, et al. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry. 2005 Oct 1;58(7):589–594. [PubMed: 16239162]
417.
Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009 Oct;70(10):1441–1451. [PubMed: 19906348]
418.
Tramontina S, Zeni CP, Ketzer CR, Pheula GF, Narvaez J, Rohde LA. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry. 2009 May;70(5):756–764. [PubMed: 19389329]
419.
Wagner KD, Nyilas M, Johnson B, et al. Long-term efficacy of aripiprazole in children 10–17 years old) with mania [poster]. Paper presented at: 54th American Academy of Child and Adolescent Psychiatry (AACAP); 2007; Boston, MA.
420.
Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007 Oct;164(10):1547–1556. [PubMed: 17898346]
421.
AstraZeneca. 2007. (D1441C00149) A 3-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo controlled, Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL™). Immediate-release Tablets in Daily Doses of 400 mg and 600 mg Compared with Placebo in the Treatment of Children and Adolescents with Bipolar I Mania.
422.
DelBello MP, Chang K, Welge JA, et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disorders. 2009;11(5):483–493. [PubMed: 19624387]
423.
Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1216–1223. [PubMed: 12364843]
424.
DelBello MP, Kowatch RA, Adler CM, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2006 Mar;45(3):305–313. [PubMed: 16540815]
425.
Rademacher J, DelBello MP, Adler C, Stanford K, Strakowski SM. Health-related quality of life in adolescents with bipolar I disorder. J Child Adolesc Psychopharmacol. 2007;17(1):97–103. [PubMed: 17343557]
426.
MacMillan CM, Withney JE, Korndorfer SR, Tilley CA, Mrakotsky C, Gonzalez-Heydrich JM. Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder. Journal of Psychiatric Practice. 2008 May;14(3):160–169. [PubMed: 18520785]
427.
Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disorders. 2009 Nov;11(7):687–700. [PubMed: 19839994]
428.
Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry. 2004 Jul;65(7):975–981. [PubMed: 15291687]
429.
Seo H-J, Jung Y-E, Woo YS, Jun T-Y, Chae J-H, Bahk W-M. Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting. Human Psychopharmacology. 2009 Mar;24(2):135–143. [PubMed: 19156709]
430.
El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology. 2010 [PubMed: 20175941]
431.
Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009 Apr;70(4):540–549. [PubMed: 19358791]
432.
Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. Cns Spectrums. 2009 Apr;14(4):197–206. [PubMed: 19407731]
433.
Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007 Jun;68(6):843–853. [PubMed: 17592907]
434.
Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety. 2006;23(6):364–372. [PubMed: 16710853]
435.
Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry. 2007 Jul;68(7):1071–1077. [PubMed: 17685744]
436.
Garakani A, Martinez JM, Marcus S, et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol. 2008 Sep;23(5):269–275. [PubMed: 18703936]
437.
Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res. 2009 Jan;43(3):205–214. [PMC free article: PMC3685867] [PubMed: 18586273]
438.
Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. [summary for patients in Ann Intern Med. 2007 Nov 6;147(9):I34; PMID: 17975178] Ann Intern Med. 2007 Nov 6;147(9):593–602. [PubMed: 17975181]
439.
Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008 Apr;28(2):156–165. [PubMed: 18344725]
440.
McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007;24(7):487–494. [PubMed: 17177199]
441.
Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology. 2006 Nov;31(11):2505–2513. [PubMed: 16760927]
442.
Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008 Aug;69(8):1228–1336. [PubMed: 18681749]
443.
Schule C, Baghai TC, Eser D, et al. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. World Journal of Biological Psychiatry. 2007;8(2):112–122. [PubMed: 17455104]
444.
Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1):131–134. [PubMed: 11136647]
445.
Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005 Oct;66(10):1289–1297. [PubMed: 16259543]
446.
Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007 Feb;68(2):224–236. [PubMed: 17335320]
447.
Yargic L, Corapcioglu A, Kocabasoglu N, Erdogan A, Koroglu G, Yilmaz D. A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. International Journal of Psychiatry in Clinical Practice. 2004;8(4):205–211. [PubMed: 24930548]
448.
Astrazeneca. 2007. (D1448C00004) A multi-centre, double-blind, randomised, parallel group, placebo-controlled and active controlled phase III study of the efficacy and safety of quetiapine fumarate extended release (seroquel XR TM) as monotherapy in the treatment of adult patients with major depressive disorder (AMBER STUDY)
449.
AstraZeneca. 2008. (D1448C00003) A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (SEROQUEL XR) as Mono-Therapy in the Treatment of Adult Patients with Major Depressive Disorder (OPAL STUDY)
450.
AstraZeneca. 2008. (D1448C00005) A Multicenter, Double-blind, Randomized-withdrawal, Parallel-group, Placebo controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (SEROQUEL XR™) as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilization Period (AMETHYST STUDY)
451.
AstraZeneca. 2008. (D1448C000014) A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Extended-Release (Seroquel XRTM) as Mono-Therapy in the Treatment of Elderly Patients with Major Depressive Disorder (SAPPHIRE STUDY)
452.
Chaput Y, Magnan A, Gendron A. The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial. BMC Psychiatry. 2008;8:73. [PMC free article: PMC2553785] [PubMed: 18752690]
453.
Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Astrom M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 2009 Apr;70(4):526–539. [PubMed: 19358790]
454.
Weisler R, Joyce J, McGill L, Lazarus A, Szamosi J, Eriksson H. Extended release quetiapine fumarate monotherapy for major depressive disorder: Results of a double-blind, randomized, placebo-controlled study. Cns Spectrums. 2009;14(6):299–313. [PubMed: 19668121]
455.
Alexopoulos GS, Canuso CM, Gharabawi GM, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry. 2008 Jan;16(1):21–30. [PMC free article: PMC2788739] [PubMed: 17928573]
456.
Weisler RH, Swanink R, Pikalov A, et al. Analysis of suicidality in pooled data from two double-blind, placebo-controlled aripiprazole adjunctive therapy trials in Major Depressive Disorder (studies CN138-139 and CN138-163) [poster]. Paper presented at: 46th American College of Neuropsychopharmacology (ACNP) Annual Meeting; Dec 9 – Dec 13, 2007; Boca Raton, Florida.
457.
Weisler R, Eiriksson H, Earley W, et al. Extended-release quetiapine fumarate (quetiapine XR) in major depressive disorder (MDD): suicidality data from acute and maintenance studies [poster]. Paper presented at: 162nd Annual Meeting of the American Psychiatric Association; May 16–21, 2009; San Francisco, CA. 2009.
458.
AstraZeneca. 2000. (D1448C00006) A Multicenter, Double-blind, Randomized, Parallel-group, Placebo controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Extended-release (SEROQUEL XR™) in Combination with an Antidepressant in the Treatment of Patients with Major Depressive Disorder with Inadequate Response to an Antidepressant Treatment (Pearl Study) p. 7.
459.
Arbaizar B, Dierssen-Sotos T, Gomez-Acebo I, Llorca J. Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. Gen Hosp Psychiatry. 2009 Sep–Oct;31(5):478–483. [PubMed: 19703642]
460.
Thase M, Trivedi MH, Swanink R, et al. Efficacy of adjunctive aripiprazole in Major Depressive Disorder: a pooled subpopulation analysis (studies CN138-139 and CN138-163) [poster]. Paper presented at: 46th American College of Neuropsychopharmacology (ACNP) Annual Meeting; 2007; Boca Raton, Florida.
461.
Ballard, Waite, Birks Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease [Systematic Review] Cochrane Database of Systematic Reviews. 2007;4:4.
462.
Kryzhanovskaya LA, Jeste DV, Young CA, et al. A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia. Journal of Clinical Psychiatry. 2006 2006 Jun;67(6):933–945. [PubMed: 16848653]
463.
Schneider LS, Dagerman K, Insel PS. American Journal of Geriatric Psychiatry. 3. Vol. 14. Mar, 2006. 2006. Efficacy and Adverse Effects of Atypical Antipsychotics for Dementia: Meta-analysis of Randomized, Placebo-Controlled Trials; pp. 191–210. [PubMed: 16505124]
464.
Schneider LS, Dagerman KS, Insel P. Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia: Meta-analysis of Randomized Placebo-Controlled Trials. JAMA: Journal of the American Medical Association. 2005 2005 Oct;294(15):1934–1943. [PubMed: 16234500]
465.
Sink KM, Holden KF, Yaffe K. Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence. JAMA: Journal of the American Medical Association. 2005 Feb;293(5):596–608. [PubMed: 15687315]
466.
van lers el MB, Zuidema SU, Koopmans RT, Verhey FR, Rikkert MG. Antipsychotics for Behavioural and Psychological Problems in Elderly People and with Dementia: A Systematic Review of Adverse Events. Drugs and Aging. 2005;22(10):2005, 845–858. [PubMed: 16245958]
467.
Mazzucco S, Cipriani A, Barbui C, Monaco S. Antipsychotic drugs and cerebrovascular events in elderly patients with dementia: a systematic review. Mini-Reviews in Medicinal Chemistry. 2008 Jul;8(8):776–783. [PubMed: 18673133]
468.
Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006 Oct 12;355(15):1525–1538. [PubMed: 17035647]
469.
Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008 Jul;165(7):844–854. [PMC free article: PMC2714365] [PubMed: 18519523]
470.
Fontaine CS, Hynan LS, Koch K, Martin-Cook K, Svetlik D, Weiner MF. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry. 2003;64(6):726–730. [PubMed: 12823090]
471.
Ellingrod VL, Schultz SK, Ekstam-Smith K, Kutscher E, Turvey C, Arndt S. Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. Pharmacotherapy. 2002;22(1 I):1–5. [PubMed: 11794418]
472.
Gareri P, Cotroneo A, Lacava R, et al. Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD) Archives of Gerontology & Geriatrics - Supplement. 2004;(9):207–215. [PubMed: 15207416]
473.
Mulsant BH, Gharabawi GM, Bossie CA, et al. Correlates of Anticholinergic Activity in Patients With Dementia and Psychosis Treated With Risperidone or Olanzapine. J Clin Psychiatry. 2004 Dec;65(12):1708–1714. [PubMed: 15641877]
474.
Deberdt W, et al. Comparison of Olanzapine and Risperidone in the Treatment of Psychosis and Associated Behavioral Disturbances in Patients With Dementia. Am J Geriatr Psychiatry. 2005;13(8) [PubMed: 16085789]
475.
Rainer M, Haushofer M, Pfolz H, Struhal C, Wick W. Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: Efficacy, safety and cognitive function. European Psychiatry. 2007 2007 Sep;22(6):395–403. [PubMed: 17482432]
476.
Shigenobu K, Ikeda M, Fukuhara R, et al. Reducing the burden of caring for Alzheimer’s disease through the amelioration of “delusions of theft” by drug therapy. Int J Geriatr Psychiatry. 2002;17(3):211–217. [PubMed: 11921147]
477.
Wancata J. Efficacy of risperidone for treating patients with behavioral and psychological symptoms of dementia. Int Psychogeriatr. 2004 Mar;16(1):107–115. [PubMed: 15191000]
478.
Edell WS, Tunis SL. Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients. Am J Geriatr Psychiatry. 2001;9(3):289–297. [PubMed: 11481138]
479.
Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G. Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study. J Neurol. 2005 Oct;252(10):1186–1193. [PubMed: 15809822]
480.
Verhey FRJ, Verkaaik M, Lousberg R. Olanzapine-Haloperidol in Dementia Study g. Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. Dement Geriatr Cogn Disord. 2006;21(1):1–8. [PubMed: 16244481]
481.
Anonymous. A multicenter, double-blind, randomized comparison of the efficacy and safety of quetiapine fumarate (SEROQUEL[TM]) and placebo in the treatment of agitation associated with dementia. ClinicalTrialsgov. 2009. [ wwwclinicaltrialsgov]
482.
Savaskan E, Schnitzler C, Schroder C, Cajochen C, Muller-Spahn F, Wirz-Justice A. Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer’s disease: haloperidol vs. quetiapine. International Journal of Neuropsychopharmacology. 2006 Oct;9(5):507–516. [PubMed: 16316485]
483.
Tariot PN, Schneider L, Katz IR, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006 Sep;14(9):767–776. [PubMed: 16905684]
484.
Chan WC, Lam LC, Choy CN, Leung VP, Li SW, Chiu HF. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry. 2001;16(12):1156–1162. [PubMed: 11748775]
485.
De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53(5):946–955. [PubMed: 10496251]
486.
Suh G-H, Greenspan AJ, Choi S-K. Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. Int J Geriatr Psychiatry. 2006 Jul;21(7):654–660. [PubMed: 16821257]
487.
AstraZeneca. A multicentre, double-blind, randomised, parallel-group comparison of quetiapine and haloperidol in the treatment of elderly patients presenting with dementia and psychoses (5077IL/0049) AstraZeneca Clinical Trials. 2009. [ wwwastrazenecaclinicaltrialscom]
488.
De Deyn P, Jester D, Swanink R, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer’s disease: a randomized, placebo-controlled study. J Clin Psychopharmacol. 2005;25(5):463–467. [PubMed: 16160622]
489.
Mintzer J, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD. Aripiprazole for the treatment of psychosis in institutionalized patients with alzheimer dementia: A multicenter, randomized, double-blind placebo controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007;15(11):918–931. [PubMed: 17974864]
490.
Streim JE, Porsteinsson AP, Breder CD, et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. AmJ Geriatr Psychiatry. 2008 Jul;16(7):537–550. [PubMed: 18591574]
491.
De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 2004 Feb;19(2):115–126. [PubMed: 14758577]
492.
Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2000;57(10):968–976. [PubMed: 11015815]
493.
Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Current Alzheimer Research. 2007 Feb;4(1):81–93. [PubMed: 17316169]
494.
Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease: randomised double blind placebo controlled trial. BMJ. 2005 Apr 16;330(7496):874. [PMC free article: PMC556156] [PubMed: 15722369]
495.
Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64(2):134–143. [PubMed: 12633121]
496.
Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry. 1999;60(2):107–115. [PubMed: 10084637]
497.
Mintzer J, et al. Risperidone in the treatment of psychosis of Alzheimer Disease: Results from a prospective clinical trial. Am J Geriatr Psychiatry. 2006;14:280–291. [PubMed: 16505133]
498.
Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002;26(4):494–504. [PubMed: 11927174]
499.
Rappaport SA, Marcus RN, Manos G, McQuade RD, Oren DA. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer’s, vascular, or mixed dementia. Journal of the American Medical Directors Association. 2009 Jan;10(1):21–27. [PubMed: 19111849]
500.
Zheng L, Mack WJ, Dagerman KS, et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients: the CATIE-AD study. Am J Psychiatry. 2009 May;166(5):583–590. [PMC free article: PMC2891018] [PubMed: 19369318]
501.
Dinca O, Paul M, Spencer NJ. Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders. J Psychopharmacol (Oxf) 2005 Sep;19(5):521–532. [PubMed: 16166190]
502.
Jensen PS, Buitelaar J, Pandina GJ, Binder C, Haas M. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adolesc Psychiatry. 2007 Mar;16(2):104–120. [PubMed: 17075688]
503.
Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database of Systematic Reviews. 2007;(1):CD005040. [PubMed: 17253538]
504.
Canitano R, Scandurra V. Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents. Neuropsychiatric Disease and Treatment. 2008;4(4):723–730. [PMC free article: PMC2536539] [PubMed: 19043516]
505.
Parikh MS, Kolevzon A, Hollander E. Psychopharmacology of aggression in children and adolescents withautism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol. 2008 Apr;18(2):157–178. [PubMed: 18439113]
506.
McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry. 2005 Jun;162(6):1142–1148. [PubMed: 15930063]
507.
Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry. 2005 Jul;162(7):1361–1369. [PubMed: 15994720]
508.
Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5) [PubMed: 15492353]
509.
McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314–321. [PubMed: 12151468]
510.
Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol. 2006 Oct;16(5):575–587. [PubMed: 17069546]
511.
Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol. 2006 Jun;21(6):450–455. [PubMed: 16948927]
512.
Troost P, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry. 2005;44(1):1137–1144. [PubMed: 16239862]
513.
Marcus RN, Owen R, Kamen l, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009 Nov;48(11):1110–1119. [PubMed: 19797985]
514.
Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009 Dec;124(6):1533–1540. [PubMed: 19948625]
515.
Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006 Oct;16(5):541–548. [PubMed: 17069543]
516.
Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry. 2001;40(8):887–894. [PubMed: 11501687]
517.
Corey-Lisle P, Guo Z, Manos G, et al. Effect of aripiprazole on quality of life and caregiver strain in the treatment of irritability associated with autistic disorder (CN139-178/179) [poster]. Paper presented at: 162nd American Psychiatric Association (APA) Annual Meeting; May 16–21, 2009; San Francisco, CA.
518.
Kamen L, Owen R, Kim J, et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder. Paper presented at: 162nd American Psychiatric Association (APA) Annual Meeting; 2009; San Francisco, CA.
519.
Miral S, Gencer O, Inal-Emiroglu FN, Baykara B, Baykara A, Dirik E. Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry. 2008 Feb;17(1):1–8. [PubMed: 18080171]
520.
Gencer O, Emiroglu FNI, Miral S, Baykara B, Baykara A, Dirik E. Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. Eur Child Adolesc Psychiatry. 2008 Jun;17(4):217–225. [PubMed: 18026891]
521.
Casaer P, Croonenberghs J, Lagae L, Deboutte D. Risperidone in the treatment of childhood autistic disorder: an open pilot study. Acta Neuropsychiatrica. 2002;14(5):242–249. [PubMed: 26984464]
522.
Corson AH, Barkenbus JE, Posey DJ, Stigler KA, McDougle CJ. A Retrospective Analysis of Quetiapine in the Treatment of Pervasive Developmental Disorders. J Clin Psychiatry. 2004 Nov;65(11):1531–1536. [PubMed: 15554768]
523.
Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull. 1997;33(1):155–159. [PubMed: 9133768]
524.
Gagliano A, Germano E, Pustorino G, et al. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol. 2004;14(1):39–47. [PubMed: 15142390]
525.
Masi G, Cosenza A, Mucci M, De Vito G. Risperidone monotherapy in preschool children with pervasive developmental disorders. J Child Neurol. 2001;16(6):395–400. [PubMed: 11417603]
526.
Nicolson R, Awad G, Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry. 1998;37(4):372–376. [PubMed: 9549957]
527.
Somer Diler R, Firat S, Avci A. An open-label trial of risperidone in children with autism. Current Therapeutic Research. 2002;63(1):91–102.
528.
Vercellino F, Zanotto E, Giambattista R, Veneselli E. Open-label risperidone treatment of 6 children and adolescents with autism. Canadian Journal of Psychiatry. 2001;46(6):559–560. [PubMed: 11526814]
529.
Hardan A, et al. NR163: Quetiapine open-label trial in children and adolescents with developmental disorders. Paper presented at: 156th Annual Meeting of the American Psychiatric Association; May 17–22, 2003; San Francisco, California.
530.
Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41(9):1026–1036. [PubMed: 12218423]
531.
Findling RI, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000;39(4):509–516. [PubMed: 10761354]
532.
Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159(8):1337–1346. [PubMed: 12153826]
533.
Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001;62(4):239–248. [PubMed: 11379837]
534.
Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry. 2006 Mar;163(3):402–410. [PubMed: 16513860]
535.
Connor DF, McLaughlin TJ, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J Child Adolesc Psychopharmacol. 2008 Apr;18(2):140–156. [PubMed: 18439112]
536.
Reyes M, Olah R, Csaba K, Augustyns I, Eerdekens M. Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. Eur Child Adolesc Psychiatry. 2006 Mar;15(2):97–104. [PubMed: 16523250]
537.
Aman MG, et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol. 2005;15(6):869–884. [PubMed: 16379507]
538.
Martin A, Scahill L, Anderson GM, et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry. 2004;161(6):1125–1127. [PubMed: 15169706]
539.
Findling R, Aman M, Eerdekens M, Derivan A, Lyons B. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry. 2004;161(4):677–684. [PubMed: 15056514]
540.
Lindsay RL, Leone S, Aman MG. Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders. Clin Pediatr (Phila) 2004 Jun;43(5):437–444. [PubMed: 15208748]
541.
Turgay A, Binder C, Snyder R, Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics. 2002;110(3):e34. [PubMed: 12205284]
542.
Harrison-Woolrych M, Garcia-Quiroga J, Ashton J, Herbison P. Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Saf. 2007;30(7):569–579. [PubMed: 17604408]
543.
Brecher M, Rak IW, Melvin K, Jones AM. The long-term effect of quetiapine (Seroquel) monotherapy on weight in patients with schizophrenia. International Journal of Psychiatry in Clinical Practice. 2000;4(4):287–291. [PubMed: 24926579]
544.
de Haan L, Linszen DH, Gorsira R. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. J Clin Psychiatry. 1999;60(6):364–365. [PubMed: 10401913]
545.
Hofer A, Hummer M, Kemmler G, Kurz M, Kurzthaler I, Fleischhacker W. The safety of clozapine in the treatment of first- and multiple-episode patients with treatment-resistant schizophrenia. International Journal of Neuropsychopharmacology. 2003 Sep;6(3):201–206. [PubMed: 12974985]
546.
Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;354(9193):1841–1845. [PubMed: 10584719]
547.
Koro CE, Fedder DO, L’Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: Population based nested case-control study. Br Med J. 2002 Aug;325(7358):243–247. [PMC free article: PMC117636] [PubMed: 12153919]
548.
Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry. 1992;149:689–690. [PubMed: 1349460]
549.
Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry. 1992;149(1):68–72. [PubMed: 1728188]
550.
Leslie D, Rosenheck R. Incidence of newly diagnosed diabetes attributable to atypical antipscyhotic medications. Am J Psychiatry. 2004;161(9):1709–1711. [PubMed: 15337666]
551.
Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 1998;155(6):751–760. [PubMed: 9619146]
552.
Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry. 1994;36(11):717–725. [PubMed: 7858067]
553.
Baymiller SP, Ball P, McMahon RP, Buchanan RW. Weight and blood pressure change during clozapine treatment. Clin Neuropharmacol. 2002;25(4):202–206. [PubMed: 12151907]
554.
Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: Cohort study using administrative data. Br Med J. 2002;325(7372):1070–1072. [PMC free article: PMC131181] [PubMed: 12424166]
555.
Jalenques I, Albuisson E, Tauveron I. Clozapine in treatment-resistant schizophrenic patients: Preliminary results from an open prospective study. Irish Journal of Psychological Medicine. 1996;13(1):13–18.
556.
Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry. 1995;152:183–190. [PubMed: 7840350]
557.
Karagianis JL, LeDrew KK, Walker DJ. Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up. Curr Med Res Opin. 2003;19(6):473–480. [PubMed: 14594518]
558.
Littrell KH, Petty RG, Hilligoss NM, Peabody CD, Johnson CG. Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat. 2001;21(4):217–221. [PubMed: 11777671]
559.
Moller HJ, Gagiano CA, Addington DE, Von Knorring L, Torres-Plank JF, Gaussares C. Long-term treatment of chronic schizophrenia with risperidone: An open-label, multicenter study of 386 patients. Int Clin Psychopharmacol. 1998;13(3):99–106. [PubMed: 9690975]
560.
Vieta E, Goikolea JM, Corbella B, et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: Results from a 6-month, multicenter, open study. J Clin Psychiatry. 2001;62(10):818–825. [PubMed: 11816872]
561.
Davidson M, Harvey PD, Vervarcke J, et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. Int J Geriatr Psychiatry. 2000;15:506–514. [PubMed: 10861916]
562.
Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second generation antipsychotic. J Clin Psychiatry. 2003;64(10):1250–1257. [PubMed: 14658976]
563.
Kurz M, Hummer M, Oberbauer H, Fleischbacker WW. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology (Berl) 1995;118(1):52–56. [PubMed: 7597122]
564.
Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62(2):92–100. [PubMed: 11247108]
565.
Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry. 1994;55(Suppl B):157–160. [PubMed: 7961563]
566.
Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology. 1991;41(3):369–371. [PubMed: 2006003]
567.
Wilson WH. Clinical review of clozapine treatment in a state hospital. Hosp Community Psychiatry. 1992;43(7):700–703. [PubMed: 1516900]
568.
Lieberman JA, Alvir JM. A report of clozapine-induced agranulocytosis in the United States. Incidence and risk factors. Drug Saf. 1992;7(Suppl 1):1–2. [PubMed: 1503671]
569.
Drew LR, Griffiths KM, Hodgson DM. A five year follow-up study of the use of clozapine in community practice. Aust N Z J Psychiatry. 2002;36(6):780–786. [PubMed: 12406120]
570.
Drew LR, Hodgson DM, Griffiths KM. Clozapine in community practice: a 3-year follow-up study in the Australian Capital Territory. Aust N Z J Psychiatry. 1999;33(5):667–675. [PubMed: 10544990]
571.
Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O’Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996;169(4):483–488. [PubMed: 8894200]
572.
Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology. 1994;44(12):2247–2249. [PubMed: 7991106]
573.
Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr Serv. 1998;49:1029–1033. [PubMed: 9712207]
574.
Vieta E, Reinares M, Corbella B, et al. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol. 2001;21(5):469–473. [PubMed: 11593070]
575.
Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension. A claims-based approach. Arch Gen Psychiatry. 2001;58(12):1172–1176. [PubMed: 11735847]
576.
Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive dyskinesia? J Clin Psychiatry. 1993;54(9):327–330. [PubMed: 8104929]
577.
Peacock L, Solgaard T, Lublin H, Gerlach J. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology (Berl) 1996;124(1–2):188–196. [PubMed: 8935815]
578.
Spivak B, Roitman S, Vered Y, et al. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol. 1998;21(4):245–250. [PubMed: 9704166]
579.
Modai I, Hirschmann S, Rava A, et al. Sudden death in patients receiving clozapine treatment: a preliminary investigation. J Clin Psychopharmacol. 2000;20(3):325–327. [PubMed: 10831019]
580.
Malla AK, Norman RM, Scholten DJ, Zirul S, Kotteda V. A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. J Clin Psychiatry. 2001;62(3):179–184. [PubMed: 11305704]
581.
Coulter DM, Bate A, Meyboom RH, Lindquist M, Edwards IR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. Br Med J. 2001;322(7296):1207–1209. [PMC free article: PMC31617] [PubMed: 11358771]
582.
Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry. 1999;156(6):863–868. [PubMed: 10360124]
583.
King DJ, Wager E. Haematological safety of antipsychotic drugs. J Psychopharmacol (Oxf) 1998;12(3):283–288. [PubMed: 10958256]
584.
Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry. 2002;63(12):1135–1139. [PubMed: 12523873]
585.
Etminan M, Streiner DL, Rochon PA. Exploring the Association Between Atypical Neuroleptic Agents and Diabetes Mellitus in Older Adults. Pharmacotherapy. 2003;23(11):1411–1415. [PubMed: 14620387]
586.
Lambertenghi Deliliers G. Blood dyscrasias in clozapine-treated patients in Italy. Haematologica. 2000;85(3):233–237. [PubMed: 10702809]
587.
Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry. 2001;62(4):273–281. [PubMed: 11379842]
588.
Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared to patients treated with conventional depot neuroleptic medications. J Clin Psychiatry. 1998;59:294–299. [PubMed: 9671341]
589.
Wang. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol. 2002;22(3):236–243. [PubMed: 12006892]
590.
Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000;157(6):975–981. [PubMed: 10831479]
591.
Ramaswamy K, Kozma CM, Nasrallah H. The relationship between duration of exposure and development of diabetic ketoacidosis in patients treated with olanzapine versus risperidone. Paper presented at: American College of Neuropsychopharmacology 42nd Annual Meeting; December 7–11, 2003; Puerto Rico.
592.
Brown RR, Estoup MW. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. International Clinical Psychopharmacology. 2005 2005 Mar;20(2):105–112. [PubMed: 15729087]
593.
Eberhard J, Lindstrom E, Levander S. Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course. Int Clin Psychopharmacol. 2006 Jan;21(1):35–42. [PubMed: 16317315]
594.
Hien LTT, Cumming RG, Cameron ID, et al. Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc. 2005 Aug;53(8):1290–1295. [PubMed: 16078953]
595.
Jerrell JM, McIntyre RS. Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications. Human Psychopharmacology. 2007 Aug;22(6):361–364. [PubMed: 17562519]
596.
Philippe A, Vaiva G, Casadebaig F. Data on diabetes from the French cohort study in schizophrenia. European Psychiatry. 2005 2005 Dec;20(Suppl 4):S340–344. [PubMed: 16459248]
597.
Rettenbacher MA, Ebenbichler C, Hofer A, et al. Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol. 2006 Nov;21(6):369–372. [PubMed: 17012984]
598.
Liperoti R, Onder G, Landi F, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry. 2009 Oct;70(10):1340–1347. [PMC free article: PMC3775351] [PubMed: 19906339]
599.
Barnett MJ, Wehring H, Perry PJ. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. J Clin Psychopharmacol. 2007 Dec;27(6):595–601. [PubMed: 18004126]
600.
Sumiyoshi T, Roy A, Anil AE, Jayathilake K, Ertugrul A, Meltzer HY. A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine. J Clin Psychopharmacol. 2004 Jun;24(3):345–348. [PubMed: 15118492]
601.
Smith M, Hopkins D, Peveler RC, Holt RIG, Woodward M, Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008 Jun;192(6):406–411. [PubMed: 18515889]
602.
Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008 Oct;105(1–3):175–187. [PMC free article: PMC2614656] [PubMed: 18775645]
603.
Moisan J, Gregoire J-P, Gaudet M, Cooper D. Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine. Pharmacoepidemiology & Drug Safety. 2005 Jun;14(6):427–436. [PubMed: 15786513]
604.
Trifiro G, Verhamme KMC, Ziere G, Caputi AP, Ch Stricker BH, Sturkenboom MCJM. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiology & Drug Safety. 2007 May;16(5):538–544. [PubMed: 17036366]
605.
Wang PW, et al. Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications. NEJM. 2005 Dec;353(22):2335–2341. [PubMed: 16319382]
606.
Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005 Sep;66(9):1116–1121. [PubMed: 16187768]
607.
Dear Healthcare Professional. UNK]. 2004. [Accessed 7/27/2004]. http://www​.hc-sc.gc.ca​/hpfb-dgpsa/tpd-dpt/zyprexa_hpc_e.html.
608.
Dear Healthcare Professional. UNK]. 2004. [Accessed 7/27/2004]. http://www​.hc-sc.gc.ca​/hpfb-dgpsa/tpd-dpt/risperdal1_e.html.
609.
Finkel S, Kozma C, Long S, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr. 2005 Dec;17(4):617–629. [PubMed: 16202186]
610.
Layton D, Harris S, Wilton LV, Shakir SA. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. Journal of Psychopharmacology. 2005 2005 Sep;19(5):473–482. [PubMed: 16166184]
611.
Herrmann N, Mandani M, Lanctot K. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161(6):1113–1115. [PubMed: 15169702]
612.
Percudani M, Barbui C, Fortino I, Tansella M, Petrovich L. Second-Generation Antipsychotics and Risk of Cerebrovascular Accidents in the Elderly. Journal of Clinical Psychopharmacology. 2005 2005 Oct;25(5):468–470. [PubMed: 16160623]
613.
Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular Events Among Elderly Nursing Home Patients Treated With Conventional or Atypical Antipsychotics. Journal of Clinical Psychiatry. 2005 2005 Sep;66(9):1090–1096. [PubMed: 16187764]
614.
Fuller M, Shermock K, Secic M, Grogg A. Comparitive study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy. 2003;23(8):1037–1043. [PubMed: 12921249]
615.
Gianfrancesco F, Grogg A, Mahmoud R. Differential effects of risperidone, olanzapine, clozapine and conventional antipsychotics on type II diabetes: findings from a large health plan database. J Clin Psychiatry. 2002;63:920–930. [PubMed: 12416602]
616.
Gianfrancesco F, White R, Wang R, Nasrallah H. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol. 2003a;23(4):328–335. [PubMed: 12920407]
617.
Gianfrancesco F, Grogg A, R M. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther. 2003b;25(4):1150–1171. [PubMed: 12809963]
618.
Ostbye T, Curtis L, Masselink L, et al. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. Pharmacoepidemiology & Drug Safety. 2005;14:407–415. [PubMed: 15372671]
619.
Barner JC, Worchel J, Yang M. Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among Central Texas veterans. Pharmacotherapy. 2004;24(11):1529–1538. [PubMed: 15537558]
620.
Ollendorf DA, Joyce AT, Rucker M. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. Medscape General Medicine. 2004;6(1):1–12. [PMC free article: PMC1140712] [PubMed: 15208518]
621.
Lee DW. No significant difference in the risk of diabetes mellitus during treatment with typical versus atypical antipsychotics. Results from a large observational trial. Drug Benefit Trends. 2002:46–51.
622.
Yood MU, DeLorenze G, Quesenberry CP Jr, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study. Pharmacoepidemiology & Drug Safety. 2009 Sep;18(9):791–799. [PubMed: 19526626]
623.
Dinan T. Stress and the genesis of diabetes mellitus in schizophrenia. Br J Psychiatry. 2004 Apr;47(Suppl):S72–75. [PubMed: 15056597]
624.
Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio P. Diabetes mellitus in schizophrenic patients. Compr Psychiatry. 1996;37(1):68–73. [PubMed: 8770530]
625.
Jeste D, Lacro J, Bailey A, Rockwell E, Harris MJ, Caligiuri M. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc. 1999;47(6):716–719. [PubMed: 10366172]
626.
Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414–425. [PubMed: 14992963]
627.
Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 1997;154(9):1248–1254. [PubMed: 9286184]
628.
Leppig M, Bosch B, Naber D, Hippius H. Clozapine in the treatment of 121 out-patients. Psychopharmacology (Berl) 1989;99(Suppl):S77–79. [PubMed: 2813669]
629.
Bourin M, Guitton B, Dailly E, Hery P, Jolliet P. A follow-up study of a population of schizophrenic patients treated with clozapine. Progress in Neuro Psychopharmacology & Biological Psychiatry. 2001;25(8):1481–1495. [PubMed: 11642649]
630.
Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30:235–244. [PubMed: 20473057]
Copyright © 2010 by Oregon Health & Science University, Portland, Oregon 97239. All rights reserved.
Bookshelf ID: NBK50585

Views

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...